Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
The addition of a Polygenic Risk Score to a clinical risk score in the prediction of cardiovascular disease
Session:
SESSÃO DE POSTERS 26 - CARDIOGENÉTICA EM AÇÃO!
Speaker:
Ana Débora Câmara De Sá
Congress:
CPC 2025
Topic:
J. Preventive Cardiology
Theme:
28. Risk Factors and Prevention
Subtheme:
28.2 Risk Factors and Prevention – Cardiovascular Risk Assessment
Session Type:
Cartazes
FP Number:
---
Authors:
Débora Sá; Maria Isabel Mendonça; Francisco Sousa; Gonçalo Abreu; Matilde Ferreira; Sónia Freitas; Mariana Rodrigues; Sofia Borges; Graça Guerra; António Drumond; Ana Célia Sousa; Roberto Palma Dos Reis
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Introduction:</strong> Recent research showed that adding a polygenic risk score (PRS) for cardiovascular disease (CVD) to clinical risk tools has improved risk prediction for CVD. It has been proved that this addition enhances the identification of individuals at increased risk for CV events in a real-world clinical setting.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Objective</strong>: Investigate in a regular cohort of a Southern European population whether adding a CVD-PRS to clinical SCORE2, in the form of an integrated risk tool (IRT), increased the proportion of high-risk individuals with, at least, one major CV event compared with the SCORE2.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Methods:</strong> An asymptomatic Southern European population composed of 1103 individuals (53.4 ± 6.9 years; 74.2% male) was analysed in this study. From the 33 genetic variants mostly used in our CVD-PRS, only 13 variants that presented an Hazard Ratio >1 for events were included. The additive PRS is the product sum of each individual's risk alleles, weighted by its effect size (HR). We constructed IRT using the formula W1*SCORE2 + W2*PRS, where W1 and W2 are weights determined through AUC curves validation. So, IRT<span style="color:black">= 0.6*Score2 + 0.4*PRS. We divided IRT in three categories <5%, 5%-10% e >10% we used the higher.</span> When about 60 individuals (cases) had a major event, NRI reclassification (with PRS added to SCORE2) was performed. Statistical analysis was done using R package “survIDINRI” and SPSS version 25. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">Results:</span></strong><span style="color:black"> From the 59 events occurred in the end of follow-up, 32.2% occurred in the top 20%, i.e. in the highest percentile of PRS; 16.5% occurred in the top 10%; 8.5% in the top 5%; 5.1% in the top 3% and 3.4% in the top 1%. 42.4% of individuals in the highest category in SCORE2 presented cardiovascular events. When we used the </span>integrated risk tool (combination of SCORE2 and polygenic risk score), there was a significant increase in events (8.4%) in the high-risk population.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong><span style="color:black">Conclusion:</span></strong><span style="color:black"> I</span>n a clinical situation, adding genetic information to clinical risk assessment significantly aids in identifying those at high risk for events, allowing preventive measures to be applied to a higher proportion of such individuals at high risk who went on to have a major CV event.</span></span></p> <p style="text-align:justify"> </p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site